Table 1.

Demographic information for patients in the biobank.

	HC-0m (n = 61)	HC-3m (n = 38)	A-0m (n = 92)	A-3m (n = 81)	B-0m (n = 59)	B-3m (n = 57)	C-0m (n = 34)	C-3m (n = 30)
Age (y)	47 ± 13		60 ± 15		55 ± 13		55 ± 15
Female	61% (37)		72% (66)		69% (41)		71% (24)
CPP-positive			60% (55)		78% (46)		79% (27)
RF-positive			54% (50)		66% (39)		76% (26)
DAS28-CRP			4.5 ± 1.2	2.8 ± 1.2	4.4 ± 1.2	3.2 ± 1.2	4.7 ± 1.2	3.4 ± 1.2
CRP (mg/mL)			14 ± 24	5.7 ± 15	11 ± 22	5.9 ± 14	12 ± 15	10 ± 14
ESR (mm)			32 ± 22	19 ± 14	20 ± 13	17 ± 13	28 ± 19	24 ± 15
Pain (VAS mm)			52 ± 27	22 ± 22	45 ± 26	30 ± 28	50 ± 22	42 ± 28
CD3 + T cells of PBMC (%)	60 ± 7.3	59 ± 7.5	51 ± 18	53 ± 14	49 ± 19	55 ± 13	55 ± 17	61 ± 8.4
CD19 + B cells of PBMC (%)	7.7 ± 2.7	7.6 ± 2.5	7.4 ± 4.4	8.4 ± 5	6.4 ± 3.8	7.5 ± 3.6	6.7 ± 4.1	4 ± 4.4
CD3-CD56 + NK cells of PBMC (%)	10 ± 4.6	10 ± 4.7	8.4 ± 5.1	9.2 ± 5	7.8 ± 4.2	8.7 ± 4.7	8.6 ± 5.2	8.6 ± 5
CD14 + Monocytes of PBMC (%)	17 ± 4.5	18 ± 6.1	18 ± 8.5	20 ± 8.3	18 ± 11	19 ± 10	19 ± 8.3	20 ± 7.9
Has RNA-seq	97% (59)	52% (32)	74% (68)	65% (60)	75% (44)	80% (47)	74% (25)	74% (25)
Has genotyping	93% (57)	93% (57)	95% (87)	95% (87)	93% (55)	93% (55)	91% (31)	91% (31)

CCP: cyclic citrullinated peptide, CRP: C-reactive protein, RF: rheumatic factor, DAS28-CRP: disease activity score 28, ESR: erythrocyte sedimentation rate, PBMC: peripheral blood mononuclear cells, RF: rheumatic factor, VAS: visual analog scale.

Numerical variables are reported as mean ± SD and categorical variables are reported as percentage (count).

Cohort HC: healthy controls.

Cohort A: treatment naïve, initiating Methotrexate.

Cohort B: methotrexate non-responders, initiating TNFi.

Cohort C: TNFi non-responders, initiating second biological (Supplementary Figure S2).